Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReGAtta: GEM103 in Geographic Atrophy
NCT04643886Phase 2Terminated
- Sponsor
- Gemini Therapeutics
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of GEM103 in geographic atrophy (GA), sponsored by Gemini Therapeutics. Started Jul 2020; status: terminated.
02
Drugs
GEM103
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04643886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643886.